Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
Drug Levels and Effects
Summary of Use during Lactation
Pomegranate juice contains ellagitannins and numerous polyphenols such as delphinidin, cyanidin, pelargonidin, punicalin, pedunculagin, punicalagin, gallagic, and ellagic acid as well as vitamin C and B vitamins. Administration of pomegranate juice to nursing mothers result in a change in the microbiota of breastmilk and infant stools and an increase in antioxidant content of breastmilk and infant urine. A low-quality study found that administration of pomegranate juice concentrate to nursing mothers of infants with hyperbilirubinemia hastened the infant’s improvement with phototherapy treatment. No adverse reactions to maternal pomegranate ingestion in breastfed infants have been observed.
Drug Levels
Pomegranate juice contains ellagitannins that are metabolized to ellagic acid. Intestinal bacteria convert ellagic acid to urolithins that are absorbed by the mother and can appear in breastmilk.
Maternal Levels. Twelve exclusively breastfeeding mothers of full-term infants consumed 8 fluidounces of pomegranate juice daily for 2 weeks. After 2 weeks, breastmilk samples contained a median of 10.7 nmol/L of urolithin A-glucuronide. Two women had urolithin B-glucuronide in their milk in concentrations of 0.5 and 11.9 nmol/L. In addition, the microbiome of breastmilk was altered with a decrease in Lactococcus, Subdoligranulum, and Acinetobacter, and an increase in Firmicutes such as Faecalibacterium.[1]
Infant Levels. Twelve exclusively breastfeeding mothers of full-term infants consumed 8 fluidounces of pomegranate juice daily for 2 weeks. After 2 weeks, all of their exclusively breastfed infants’ urine samples contained urolithin A-glucuronide in a median concentration of 18.1 nmol/L. The urine of 2 infants whose mothers’ milk contained urolithin B-glucuronide contained it also in a median concentration of 1.8 nmol/L. Five other infants’ urine contained dimethyl ellagic acid glucuronide in concentration ranging from 0.8 to 17.5 nmol/L.[1]
Effects in Breastfed Infants
Twelve exclusively breastfeeding mothers of full-term infants consumed 8 fluidounces of pomegranate juice daily for 2 weeks. After 2 weeks, the infant stool samples had significant increases in the abundance of bacteria from the phylum Firmicutes (genus Lachnoclostridium and Staphylococcus). Infants whose mothers’ milk contained urolithin B-glucuronide (metabotype B) showed significant differences in 4 bacteria, with 2 bacteria from the phyla Firmicutes (genus Veillonella) and Bacteroidetes (genus Bacteroides and Parabacteroides) and Bifidobacterium. Infant stool Blautia was positively corelated with breastmilk and plasma urolithin B-glucuronide and infant stool Enterococcus was inversely related to breastmilk maternal plasma urolithin B-glucuronide, and maternal plasma urolithin B-glucuronide and dimethyl ellagic acid glucuronide.[1]
An open-label, nonblinded study randomized mothers of newborn infants to receive either concentrated pomegranate juice 15 mL 3 times daily or nothing (i.e., no placebo control). There were 43 mother-infant pairs in each group. The concentrate was made from the juice of fresh pomegranates concentrated at a warm temperature to a Brix of 60%. The total phenol content was 13.56 mg/g and the total flavonoid was 1.39 mg/g. All of the infants were over 72 hours old, had a gestational age over 37 weeks and birth weight over 2500 grams. Both groups were being treated with phototherapy for hyperbilirubinemia (total serum bilirubin level over 15 mg/dL). There was a greater decrease in bilirubin levels in the pomegranate group at 48 and 72 hours after the start of phototherapy and at 48 hours after discharge. In addition, the mean duration of phototherapy in the pomegranate group was significantly shorter (52 hours compared to 65 hours) than in the no-pomegranate group. All infants in the pomegranate group were discharged by 96 hours after the start of treatment compared to 114 hours in the no-pomegranate group. No side effects were observed in the infants whose mothers received pomegranate juice concentrate.[2]
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
References
- 1.
- Henning SM, Yang J, Lee RP, et al. Pomegranate juice alters the microbiota in breast milk and infant stool: A pilot study. Food Funct 2022;13:5680-9. [PubMed: 35510588]
- 2.
- Rezapour M, Zahedpasha Y, Kamalinejad M, et al. The effect of oral use of concentrated pomegranate juice by mothers on hyperbilirubinemia in neonates under phototherapy: A randomized clinical trial. J Res Med Sci 2023;28:46. [PMC free article: PMC10366972] [PubMed: 37496646]
Substance Identification
Substance Name
Pomegranate
Scientific Name
Punica granatum
Drug Class
Breast Feeding
Milk, Human
Complementary Therapies
Food
Phytotherapy
Plants, Medicinal
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- User and Medical Advice Disclaimer
- Drugs and Lactation Database (LactMed) - Record Format
- LactMed - Database Creation and Peer Review Process
- Fact Sheet. Drugs and Lactation Database (LactMed)
- Drugs and Lactation Database (LactMed) - Glossary
- LactMed Selected References
- Drugs and Lactation Database (LactMed) - About Dietary Supplements
- Breastfeeding Links
- The potent in vitro antioxidant ellagitannins from pomegranate juice are metabolised into bioavailable but poor antioxidant hydroxy-6H-dibenzopyran-6-one derivatives by the colonic microflora of healthy humans.[Eur J Nutr. 2004]The potent in vitro antioxidant ellagitannins from pomegranate juice are metabolised into bioavailable but poor antioxidant hydroxy-6H-dibenzopyran-6-one derivatives by the colonic microflora of healthy humans.Cerdá B, Espín JC, Parra S, Martínez P, Tomás-Barberán FA. Eur J Nutr. 2004 Aug; 43(4):205-20. Epub 2004 Jan 6.
- Review Pomegranate Ellagitannins.[Herbal Medicine: Biomolecular ...]Review Pomegranate Ellagitannins.Heber D. Herbal Medicine: Biomolecular and Clinical Aspects. 2011
- Phenolic compounds as beneficial phytochemicals in pomegranate (Punica granatum L.) peel: A review.[Food Chem. 2018]Phenolic compounds as beneficial phytochemicals in pomegranate (Punica granatum L.) peel: A review.Singh B, Singh JP, Kaur A, Singh N. Food Chem. 2018 Sep 30; 261:75-86. Epub 2018 Apr 13.
- In vitro antiproliferative, apoptotic and antioxidant activities of punicalagin, ellagic acid and a total pomegranate tannin extract are enhanced in combination with other polyphenols as found in pomegranate juice.[J Nutr Biochem. 2005]In vitro antiproliferative, apoptotic and antioxidant activities of punicalagin, ellagic acid and a total pomegranate tannin extract are enhanced in combination with other polyphenols as found in pomegranate juice.Seeram NP, Adams LS, Henning SM, Niu Y, Zhang Y, Nair MG, Heber D. J Nutr Biochem. 2005 Jun; 16(6):360-7.
- Review An Insight into Anticancer Bioactives from Punica granatum (Pomegranate).[Anticancer Agents Med Chem. 2022]Review An Insight into Anticancer Bioactives from Punica granatum (Pomegranate).Sharma K, Kesharwani P, Prajapati SK, Jain A, Jain D, Mody N, Sharma S. Anticancer Agents Med Chem. 2022; 22(4):694-702.
- Pomegranate - Drugs and Lactation Database (LactMed®)Pomegranate - Drugs and Lactation Database (LactMed®)
Your browsing activity is empty.
Activity recording is turned off.
See more...